GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri
Yıl: 2021 Cilt: 69 Sayı: 2 Sayfa Aralığı: 261 - 268 Metin Dili: Türkçe DOI: 10.5578/tt.20219817 İndeks Tarihi: 01-06-2022
GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri
Öz: Astım, kronik hava yolu inflamasyonu ile karakterize heterojen bir akciğer
hastalığıdır. Önceki yıllarda hafif astım semptomları olan hastaların gereğinde kısa etkili β2-agonistlerle (SABA) iyi şekilde tedavi edilebileceği öneriliyordu. GINA, 2019 yılında köklü bir değişiklik yaparak SABA’ların hafif astımlı
hastalarda monoterapi olarak kullanılmamasını, bunun yerine semptomları
rahatlatmak ve kontrol etmek amacıyla gereğinde düşük doz inhale kortikosteroid (IKS)-formoterol veya “her SABA alındığında ek olarak düşük doz IKS”
tedavilerini önerdi. Bu önerilerin ortaya çıkmasında SABA’ların aşırı kullanımına bağlı ağır astım atakları ve astımla ilişkili ölüm riskinin arttığını gösteren
çalışmalar rol oynadı. Bu yazıda GINA 2019’da basamak 1 ve 2 tedavi
değişiklikleri, bu değişikliklerin yapılma sebepleri ve yapılan değişiklikleri
destekleyen çalışmalar anlatılacaktır.
Anahtar Kelime: GINA 2019 - step 1 and 2 treatment in asthma: Updates with reasons behind
Öz: Asthma is a heterogeneous lung disease characterized by chronic airway
inflammation. It was suggested that patients with mild asthma symptoms
could be managed with as-needed short-acting β2-agonists (SABA) in previous years. In 2019, GINA made a radical change and recommended that
SABA should not be used as monotherapy in patients with mild asthma, but
instead as-needed low-dose inhaled corticosteroid (ICS)-formoterol or
“additional low-dose ICS taken whenever SABA is taken” treatments should
be commenced to relieve and control symptoms. The approach emerged in
the light of the studies that indicate the increased risk of severe exacerbation
and asthma-related death due to overuse of SABA. The present article aimed
to enlighten the updates in GINA 2019 step 1 and 2 treatment, the grounds
for these updates with the supportive studies.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2018. Available from: www. ginasthma.org (Accessed 13 Apr 2019).
- 2. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonideformoterol as needed in mild asthma. N Engl J Med 2018; 378(20): 1865-76.
- 3. Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007; 62(6): 591-604.
- 4. Bavbek S, Çelik G, Ediger D, Mungan D, Sin B, Demirel YS et al. Severity and associated risk factors in adult asthma patients in Turkey. Ann Allerg Asthma Immun 2000: 85(2); 134-9.
- 5. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. (Accessed 10 July 2019). Available from: www.ginasthma.org
- 6. Astım Tanı ve Tedavi Rehberi 2020 Güncellemesi. Available from: www.aid.org.tr/
- 7. Global Strategy for Asthma Management and Prevention 2020 available from: www.ginasthma.org.
- 8. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600-8; 608.e1-6.
- 9. Sears MR, Lötvall J. Past, present and future-beta2-adrenoceptor agonists in asthma management. Respir Med 2005; 99: 152-70.
- 10. Bullowa JG, Kaplan DM. On the hypodermic use of adrenalin chloride in the treatment of asthmatic attacks. Med News 1903; 83: 787-90.
- 11. Herberg D, Sessner HH. First experiences with the adrenaline derivative Alupent in bronchospastic states. Dtsch Med Wochenschr 1961; 86: 1133-5.
- 12. Pavasini R, Spitaleri G, Marcantoni L, Campo G, Ferrari R. β-blockers across the cardiovascular continuum: cardioprotection and cardioselectivity. Hot Top Cardiol 2014; 9: 7-28.
- 13. Telegraph. Available from: https://www.telegraph.co.uk/ news/obituaries/finance-obituaries/8897458/Sir-DavidJack.html (Accessed 20 Jan 2020).
- 14. Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol 2012; 109: 403-7.
- 15. Crane J, Flatt A, Jackson R, Ball M, Pearce N, Burgess C, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1983: Case-control study. Lancet 1989; 1: 917-22.
- 16. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-6.
- 17. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277: 887-91.
- 18. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149(3): 604-10.
- 19. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-6.
- 20. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled betaagonist treatment. Respir Med 2000; 94: 767-71.
- 21. Aldridge RE, Hancox RJ, Robin Taylor D, Cowan JO, Winn MC, Frampton CM, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000; 161: 1459-64.
- 22. Hull SA, McKibben S, Homer K, Taylor SJ, Pike K, Griffiths C. Asthma prescribing, ethnicity and risk of hospital admission: An analysis of 35,864 linked primary and secondary care records in East London. NPJ Prim Care Respir Med 2016; 26.
- 23. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018; 391(10122): 783-800.
- 24. Miller MK, Lee JH, Miller DP, Wenzel SE, Group TS. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007; 101(3): 481-9.
- 25. Cole S, Seale C, Griffiths C. “The blue one takes a battering” why do young adults with asthma overuse bronchodilator inhalers? A qualitative study. BMJ Open 2013; 3.
- 26. Sadatsafavi M, Rousseau R, Chen W, Zhang W, Lynd L, FitzGerald JM. The preventable burden of productivity loss due to suboptimal asthma control: A populationbased study. Chest 2014; 145: 787-93.
- 27. Bateman ED et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018; 378(20): 1877-87.
- 28. Barnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015; 60(3): 455-68.
- 29. Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid/beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol 2014;133(1):39-41.
- 30. Engelkes M, Janssens HM, Jongste JC, de Sturkenboom MCJM, Verhamme KMC. Medication adherence and the risk of severe asthma exacerbations: A systematic review. Eur Respir J 2015; 45: 396-407.
- 31. Royal College of Physicians. Why Asthma Still Kills. RCP London. Available from: https://www.rcplondon.ac.uk/ projects/outputs/why-asthma-still-kills
- 32. Janson C, Menzies-Gow A, Nan C. SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries. Adv Ther 2020; 37: 1124-35.
- 33. Sobieraj DM. Association of inhaled corticosteroids and long‐acting beta‐agonists as controller and quick relief therapy with exacerbations and symptom control in persistenasthma: a systematic review and meta‐analysis. JAMA 2018; 319: 1485-96.
- 34. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356: 2040-52.
- 35. Lazarinis N, Jorgensen L, Ekstrom T, Bjermer L, Dahlen B, Pullerits T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014; 69: 130-6.
- 36. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al; Novel START Study Team. Controlled trial of budesonide‐formoterol as needed for mild asthma. N Engl J Med 2019; 380: 2020-30.
- 37. Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R; PRACTICAL study. Lancet 2019; 14; 394(10202):919-.
| APA | Cengiz A, Bavbek S (2021). GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . , 261 - 268. 10.5578/tt.20219817 |
| Chicago | Cengiz Ali,Bavbek Sevim GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . (2021): 261 - 268. 10.5578/tt.20219817 |
| MLA | Cengiz Ali,Bavbek Sevim GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . , 2021, ss.261 - 268. 10.5578/tt.20219817 |
| AMA | Cengiz A,Bavbek S GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . . 2021; 261 - 268. 10.5578/tt.20219817 |
| Vancouver | Cengiz A,Bavbek S GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . . 2021; 261 - 268. 10.5578/tt.20219817 |
| IEEE | Cengiz A,Bavbek S "GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri ." , ss.261 - 268, 2021. 10.5578/tt.20219817 |
| ISNAD | Cengiz, Ali - Bavbek, Sevim. "GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri ". (2021), 261-268. https://doi.org/10.5578/tt.20219817 |
| APA | Cengiz A, Bavbek S (2021). GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . Tüberküloz ve Toraks, 69(2), 261 - 268. 10.5578/tt.20219817 |
| Chicago | Cengiz Ali,Bavbek Sevim GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . Tüberküloz ve Toraks 69, no.2 (2021): 261 - 268. 10.5578/tt.20219817 |
| MLA | Cengiz Ali,Bavbek Sevim GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . Tüberküloz ve Toraks, vol.69, no.2, 2021, ss.261 - 268. 10.5578/tt.20219817 |
| AMA | Cengiz A,Bavbek S GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . Tüberküloz ve Toraks. 2021; 69(2): 261 - 268. 10.5578/tt.20219817 |
| Vancouver | Cengiz A,Bavbek S GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri . Tüberküloz ve Toraks. 2021; 69(2): 261 - 268. 10.5578/tt.20219817 |
| IEEE | Cengiz A,Bavbek S "GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri ." Tüberküloz ve Toraks, 69, ss.261 - 268, 2021. 10.5578/tt.20219817 |
| ISNAD | Cengiz, Ali - Bavbek, Sevim. "GINA 2019 - astımda basamak 1 ve 2 tedavisi: Değişiklikler ve nedenleri ". Tüberküloz ve Toraks 69/2 (2021), 261-268. https://doi.org/10.5578/tt.20219817 |
